Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
Silvant Capital Management LLC has acquired a new position of 18,126 shares, valued at $5.46 million, in Alnylam Pharmaceuticals. This comes as Alnylam reported strong Q2 earnings per share, surpassing consensus estimates, though revenue slightly missed expectations. Analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $386.62, despite recent downward revisions from some firms and a 5.5% drop in share price at opening.
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors E
Kirby McInerney LLP is investigating potential securities law violations by Alnylam Pharmaceuticals, Inc. following a significant drop in its stock price. This decline occurred after Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to a normalization of growth in the ATTR-CM market. Investors who purchased Alnylam securities are encouraged to contact Kirby McInerney LLP to discuss their rights.
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY)
Alnylam Pharmaceuticals recently cut its 2026 full-year TTR product sales guidance due to reassessed growth expectations for the ATTR-CM market. This reduction in sales outlook, coupled with an ongoing legal investigation into potential federal securities law violations, introduces uncertainty for investors. The developments highlight Alnylam's dependence on TTR demand and may influence its valuation.
Bragar Eagel & Squire, P.C. is Investigating Alnylam
Bragar Eagel & Squire, P.C. announced an investigation into Alnylam Pharmaceuticals, Inc. on behalf of its stockholders. The investigation follows a significant drop in Alnylam's stock price after the company lowered its full-year 2026 TTR product sales guidance due to slower-than-expected growth in the ATTR-CM market. The law firm is encouraging investors who suffered losses to contact them regarding potential claims of federal securities law violations.
Securities Fraud Investigation Into Alnylam
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, causing its stock to drop significantly. The firm is urging shareholders who lost money to contact them to potentially pursue claims. The investigation focuses on whether Alnylam violated federal securities laws.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) regarding potential violations of federal securities laws. This follows Alnylam's announcement on July 30, 2026, where they lowered their full-year 2026 TTR product sales guidance, resulting in a significant drop in stock price. Shareholders who incurred losses are encouraged to contact the firm to inquire about potentially pursuing a claim.
NewEdge Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
NewEdge Advisors LLC significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 82.2% in the first quarter, selling over 10,000 shares. Despite this reduction, institutional ownership remains high at nearly 93%, with several major investors increasing their positions. Alnylam Pharmaceuticals reported strong Q1 earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating for the stock.
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating potential securities law violations by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) following a significant drop in stock price. This decline occurred after Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to evolving market conditions. Investors who purchased Alnylam securities are encouraged to contact the law firm to learn more about their rights.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for possible violations of federal securities laws. This follows Alnylam's announcement on July 30, 2026, where they lowered their TTR product sales guidance for full-year 2026, causing their stock to fall significantly. Investors who lost money are urged to contact the law firm to learn about potentially pursuing a claim.
BMO Capital Markets Initiates Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY)
BMO Capital Markets initiated coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with an "outperform" rating and a $318 price target, suggesting a 39.1% upside. This positive outlook comes despite some other firms recently lowering their price targets. Alnylam Pharmaceuticals also reported strong quarterly earnings, exceeding analyst expectations with $1.84 EPS and a 66.9% year-over-year revenue increase to $1.29 billion.
ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm
Kessler Topaz Meltzer & Check, LLP has initiated an investigation into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential violations of federal securities laws after the company reported disappointing Q2 2026 financial results and lowered its full-year TTR product sales guidance by approximately $200 million. Following this announcement, Alnylam's stock price dropped over 28%. Investors who suffered financial losses are encouraged to contact KTMC for a discussion of their legal rights.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) on behalf of investors. This investigation follows Alnylam's announcement on July 30, 2026, of lowered full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. The firm encourages shareholders to participate in the investigation, noting that it operates on a contingency fee basis.
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam cut its full-year TTR product sales guidance by approximately $200 million, leading to a stock price drop of over 28%. The firm is encouraging investors who experienced financial losses to contact them to discuss their legal rights.
SCS Capital Management LLC Invests $34.78 Million in Alnylam Pharmaceuticals, Inc. $ALNY
SCS Capital Management LLC has invested $34.78 million in Alnylam Pharmaceuticals, acquiring 115,549 shares, which represents about 0.09% of the company. Institutional investors now own 92.97% of Alnylam's stock, while analysts maintain a "Moderate Buy" rating with an average price target of $393.86, despite some recent price target reductions. The stock opened at $228.65, significantly below its one-year high.
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Alnylam Pharmaceuticals has experienced a significant stock sell-off due to lowered revenue guidance for its ATTR products and competition from BridgeBio. However, the article argues that the market reaction is overdone, highlighting Amvuttra's strong sales growth, a favorable competitive landscape after a rival drug's failure, and Alnylam's confident future outlook and attractive valuation. The author suggests that investors are missing the full positive story and a potential buying opportunity.
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential federal securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam significantly lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop over 28%. Investors who suffered losses are encouraged to contact the law firm to discuss their legal rights.
ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256
Wells Fargo has maintained an Equal-Weight rating for Alnylam Pharmaceuticals (ALNY), lowering its price target from $316.00 to $256.00, an 18.99% decrease. Despite this, GuruFocus indicates ALNY is significantly undervalued at $223.22 compared to its GF Value™ of $528.81, showing a 57.8% undervaluation and a solid GF Score™ of 70/100. Insider selling activity, however, suggests a cautious sentiment.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company
Wells Fargo & Company has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $316.00 to $256.00, while maintaining an "equal weight" rating. This adjustment implies a potential upside of 14.71% from the stock's previous close. Despite this reduction and similar moves by other analysts, the consensus rating for Alnylam Pharmaceuticals remains a "Moderate Buy" with an average price target of $393.86.
Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test
Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, leading to significant share price pressure. Despite a "most popular narrative" suggesting the stock is 47.8% undervalued with a fair value of $434.72, this valuation relies on ambitious growth and profitability assumptions, including strong uptake of AMVUTTRA. The article questions whether these long-term assumptions remain realistic given the recent setbacks and highlights that the current P/E ratio is already high compared to the industry.
Securities Fraud Investigation Into Alnylam
Glancy Prongay Wolke & Rotter LLP is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for possible violations of federal securities laws. The investigation stems from Alnylam's revised 2026 TTR product sales guidance, which led to a significant drop in its stock price on July 30, 2026. Shareholders who lost money are encouraged to contact the law firm to explore potential claims.
Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test
Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, causing its stock price to drop significantly. Despite a current "undervalued" narrative with a fair value of $434.72 against its $227.12 close, this valuation relies on ambitious growth and profitability assumptions that are now being re-evaluated in light of the
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318
Stifel has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US) and maintained its target price of $318. This indicates the firm's continued confidence in the company's stock performance.
Securities Fraud Investigation Into Alnylam
Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Alnylam Pharmaceuticals, Inc. (ALNY) following a significant drop in its stock price. The investigation stems from Alnylam lowering its TTR product sales guidance for full-year 2026, leading to an $81.25 (28.35%) intraday decline in share price on July 30, 2026. The law firm is urging investors who lost money to contact them to potentially pursue claims under federal securities laws.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for potential violations of federal securities laws. This follows Alnylam's announcement on July 30, 2026, where the company lowered its full-year 2026 TTR product sales guidance by approximately $200 million, leading to a significant drop in its stock price. Shareholders who incurred losses are encouraged to contact the firm to inquire about pursuing claims.
Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)?
Alnylam Pharmaceuticals reported strong Q2 2026 revenues of US$1.29 billion and net income of US$164.49 million, with H1 revenues reaching US$2.46 billion and net income at US$370.49 million. However, the company adjusted its full-year 2026 guidance, lowering net product revenue expectations while increasing collaboration and royalty income. This shift highlights a changing investment narrative, moving from pure AMVUTTRA upside to the importance of partnered programs and royalties in offsetting franchise volatility, even as analysts' long-term forecasts for 2029 remain robust.
Handelsbanken Fonder AB Sells 29,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Handelsbanken Fonder AB reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 21.4% in the second quarter, selling 29,207 shares and retaining 107,255 shares valued at $32.3 million. Despite this, institutional investors collectively own 92.97% of the company's stock, with several major funds increasing their positions. Alnylam Pharmaceuticals currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $396.72 against a recent share price of $221.20.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop significantly. The investigation encourages investors who purchased Alnylam securities to connect with the firm to assist in the process. The firm operates on a contingency fee basis for class actions.
Drugs that missed the mark in pharma’s last earnings round
This article discusses how several blockbuster drugs from major pharmaceutical companies like Alnylam, Merck, AbbVie, and Roche underperformed analyst expectations in the last quarter. Factors contributing to this underperformance include competition, evolving market conditions, and changes in regulatory policies. Despite these setbacks, the companies generally maintain confidence in their products' long-term potential.
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has shown significant outperformance over the past two decades, with an annualized return of 15.23%. An initial investment of $1000 in ALNY stock 20 years ago would now be valued at $17,192.61. This highlights the substantial impact of compounded returns on investment growth over time.
PensionDanmark Pensionsforsikringsaktieselskab Sells 12,119 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
PensionDanmark Pensionsforsikringsaktieselskab reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 35.1% in the second quarter, selling 12,119 shares and retaining 22,451 shares valued at $6.76 million. The stock opened at $219.20, significantly below its 52-week high, with institutional investors owning nearly 93% of the company. Analyst sentiment remains a "Moderate Buy" with a consensus price target of $396.72, despite recent target reductions by some firms.
Assenagon Asset Management S.A. Has $46.87 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Assenagon Asset Management S.A. increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 20.8% in the second quarter, bringing its total holdings to 155,695 shares valued at $46.87 million. Other institutional investors also significantly adjusted their positions, and institutional investors now collectively own 92.97% of the company. Analyst ratings are mixed but lean towards a "Moderate Buy" with an average price target of $396.72, despite some recent price target reductions and a director selling shares.
Alnylam Pharmaceuticals, Inc. (ALNY) latest press releases and corporate news
This article provides a compilation of recent press releases and corporate news related to Alnylam Pharmaceuticals (ALNY). It lists various announcements from the last several months, including financial results, biomarker collaboration reports, webcast details for earnings calls, and updates on neuroscience programs. The page also includes current stock performance data for ALNY and other market indices.
Empowered Funds LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY
Empowered Funds LLC significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 72.2% in the first quarter, selling 14,021 shares and retaining 5,410 shares valued at $1.79 million. Despite this, analysts maintain a "Moderate Buy" consensus rating, although some major firms recently cut their price targets for ALNY. The stock opened at $216.12, reflecting a 5.5% decline, and institutional investors collectively own 92.97% of the company.
Alnylam Pharmaceuticals (ALNY) On Lowered TTR Guidance And What It Means For Valuation
Alnylam Pharmaceuticals (ALNY) experienced a significant share price drop after lowering its 2026 TTR product sales guidance, despite strong quarterly revenue. While analysts consider the stock 47.4% undervalued with a consensus price target of $434.72, its current P/E ratio is higher than industry averages, indicating potential valuation risk if expectations shift further. The article suggests investors review underlying data due to mixed sentiment.
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history
This article provides a comprehensive overview of Alnylam Pharmaceuticals, Inc. (ALNY), including its current stock price, recent performance metrics, and key financial data. It details the company's various therapeutic products, both commercialized and in different phases of clinical trials, focusing on its RNA interference-based treatments. The report also highlights analyst ratings, valuation measures, and comparative performance against competitors within the biotechnology sector.
Alnylam Pharmaceuticals (ALNY) On Lowered TTR Guidance And What It Means For Valuation
Alnylam Pharmaceuticals (ALNY) experienced a significant intraday share price drop following lowered 2026 TTR product sales guidance, despite strong quarterly revenues. The company's stock has been under pressure for much of 2026, yet analysts maintain a consensus price target of $434.72, suggesting it is 47.4% undervalued. However, the valuation hinges on successful Amvuttra execution and stable pricing, with sensitivity to any setbacks in the TTR franchise.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) following a significant drop in its stock price. This investigation stems from Alnylam lowering its full-year 2026 TTR product sales guidance by approximately $200 million, leading to a 28.35% intraday stock drop on July 30, 2026. The firm encourages Alnylam stockholders to connect to assist in the investigation.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
Implied volatility for Alnylam Pharmaceuticals (ALNY) stock options is surging, particularly for the Sep 18, 2026 $170 Call, indicating that the market expects a significant price movement. Despite this, analysts currently rate Alnylam Pharmaceuticals as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates, suggesting potential trading opportunities for options traders. This high implied volatility could be attractive for options traders looking to sell premium.
Alnylam Pharmaceuticals, Inc. (ALNY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. The firm is encouraging investors who purchased Alnylam securities to contact them to learn more and assist with the investigation. The investigation stems from Alnylam's announcement on July 30, 2026, where it reduced projected TTR net product revenues by approximately $200 million due to evolving market conditions.
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of its stockholders. This investigation follows Alnylam's announcement of lowered TTR product sales guidance for full-year 2026, leading to a significant drop in its stock price. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.
ALNYLAM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $455 FROM $485
H.C. Wainwright has revised its target price for Alnylam Pharmaceuticals, Inc. (ALNY) shares, lowering it to $455 from the previous $485. This report, disseminated by Reuters, indicates an updated analyst perspective on the company's valuation. The content emphasizes that this analysis is an opinion and not investment advice.
Securities Fraud Investigation into Alnylam
Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance. This reduction, announced on July 30, 2026, was attributed to evolving market conditions and resulted in an approximate $200 million decrease in projected TTR net product revenues. Consequently, Alnylam's stock fell sharply, injuring investors who are now urged to contact the law firm to pursue potential claims.
ALNYLAM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $455 FROM $485
H.C. Wainwright has revised its target price for ALNYLAM PHARMACEUTICALS, INC., lowering it to $455 from the previous $485. This adjustment was reported by Reuters. The article itself is brief, focusing solely on this target price change.
Alnylam (ALNY) Turns Profitable as Revenue Mix Shifts: What Changes in Its Investment Story?
Alnylam Pharmaceuticals (ALNY) turned profitable in Q2 2026, reporting US$1,290.95 million in revenue and US$164.49 million in net income. The company also updated its full-year guidance, trimming net product revenue expectations while increasing collaboration and royalty revenue forecasts, indicating a shift in its sales generation mix. This change, while positive for profitability, emphasizes the importance of TTR franchise execution, cost discipline, and managing pricing pressures for its long-term investment narrative.
Securities Fraud Investigation into Alnylam
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance. This reduction, announced on July 30, 2026, led to a significant drop in Alnylam's stock price, injuring investors. Shareholders who lost money are encouraged to contact the firm to learn about potentially pursuing claims.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for potential violations of federal securities laws. This investigation follows Alnylam's announcement on July 30, 2026, where the company lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to evolving market conditions. Consequently, Alnylam's shares dropped significantly, injuring investors who are now urged to contact the law firm to learn about potentially recovering their losses.
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by Alnylam Pharmaceuticals, Inc. (ALNY). This probe follows Alnylam's announcement on July 30, 2026, of lowered full-year 2026 product sales guidance due to slower-than-expected growth in the second-line ATTR-CM market, which caused a significant drop in its stock price. Shareholders who suffered losses are encouraged to contact SBS Law for a free consultation.
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) following a significant drop in stock price. This investigation stems from the company's lowered TTR product sales guidance for full-year 2026, which led to a nearly 28.4% decline in shares after its Q2 2026 financial results announcement. SBS is looking into whether Alnylam made false or misleading statements to investors.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its securities fraud investigation into Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. The investigation concerns potential violations of federal securities laws. Shareholders who lost money are encouraged to contact the law firm to learn about pursuing a claim.
ALNYLAM PHARMACEUTICALS INC : RAYMOND JAMES CUTS TARGET PRICE TO $420 FROM $468
Raymond James has adjusted its target price for Alnylam Pharmaceuticals Inc., lowering it to $420 from the previous $468. This change indicates an updated outlook from the financial firm regarding the biotechnology company's valuation.
